| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| Other Sizes |
| Targets |
Cyclooxygenase-2 (COX-2; PTGS2). C2 Ceramide (d14:1/2:0) is a bioactive sphingolipid that selectively binds to the COX-2 protein with strong binding affinity. It is a composition for diagnosing diseases associated with COX-2 overexpression, as disclosed in patent WO2019235824A1. By selectively targeting COX-2, it may serve as a diagnostic or targeting agent.
|
|---|---|
| ln Vitro |
In vitro, C2 Ceramide (d14:1/2:0) exhibits a strong binding activity to the COX-2 protein (information extracted from patent WO2019235824A1). It selectively targets cyclooxygenase-2 (COX-2) and has been used in research to diagnose diseases associated with COX-2 overexpression. The binding affinity and selectivity are valuable properties for the development of diagnostic probes.
|
| ln Vivo |
In vivo, dietary administration of C2 Ceramide (d14:1/2:0) (100 uM) induces lipotoxic cardiomyopathy in Drosophila by increasing diastolic and systolic diameter, reducing fractional shortening, and decreasing the number of normal cardiac contractile events. This in vivo phenotype highlights its bioactivity and potential for modeling COX-2-related cardiac pathology. No other in vivo studies are reported.
|
| Enzyme Assay |
A direct binding ELISA or surface plasmon resonance (SPR) is used to assess COX-2 binding affinity. Recombinant human COX-2 protein is immobilized on a sensor chip or microplate. Serially diluted C2 Ceramide (d14:1/2:0) (0.1-1000 uM) is flowed over. The binding affinity (e.g., Kd) and binding kinetics (association/dissociation rates) are calculated from the sensorgram or ELISA signal. This binding assay is detailed in patent WO2019235824A1.
|
| Cell Assay |
For in vitro cellular assays, cell lines with high COX-2 expression (e.g., inflamed macrophages, certain cancer cell lines) are treated with C2 Ceramide (d14:1/2:0) (1-100 uM) for 1-4 hours. Cellular binding and uptake are assessed by fluorescence microscopy or flow cytometry if a fluorescent label is attached. COX-2 protein binding is detected by co-localization with an anti-COX-2 antibody and a secondary antibody. For diagnostic applications, cells are incubated with a labeled derivative of C2 Ceramide, and COX-2 overexpression is detected by signal intensity.
|
| Animal Protocol |
The in vivo efficacy of C2 Ceramide (d14:1/2:0) has been evaluated in Drosophila as a model for lipotoxic cardiomyopathy. Adult Drosophila are fed standard food supplemented with C2 Ceramide (d14:1/2:0) at a concentration of 100 uM. After a defined feeding period (typically several days to weeks), hearts are dissected and cardiac contractile activity is assessed by high-speed video microscopy. Diastolic and systolic diameters are measured, fractional shortening is calculated, and the number of normal contractile events is counted. This assay demonstrates the in vivo bioactivity of C2 Ceramide.
|
| ADME/Pharmacokinetics |
C2 Ceramide (d14:1/2:0) has a molecular weight of 293.44 g/mol and a formula of C16H31NO3. Its IUPAC name is (S,E)-3-hydroxy-2-((1-hydroxyethylidene)amino)octadec-4-en-1-yl acetate. It is a lipid molecule with a long fatty acid chain, making it highly lipophilic (LogP >5). Due to its lipophilicity, it is soluble in DMSO and ethanol but has low aqueous solubility. In vivo, it is administered as a dietary supplement (100 uM in food) or formulated with lipid carriers for systemic administration. Detailed PK parameters are not available.
|
| Toxicity/Toxicokinetics |
Detailed toxicological data for C2 Ceramide (d14:1/2:0) are not publicly available except for the observed cardiotoxic effect in Drosophila. At a dietary concentration of 100 uM, it induces lipotoxic cardiomyopathy in flies, characterized by increased diastolic and systolic diameters, reduced fractional shortening, and decreased normal contractile events. This suggests potential cardiotoxicity at elevated concentrations. No other toxicological endpoints have been reported.
|
| References | |
| Additional Infomation |
N-[(1S,2R,3E)-2-hydroxy-1-(hydroxymethyl)-3-tridecen-1-yl]-acetamide is an organic molecular entity.
The compound is a composition described in patent WO2019235824A1. It is used primarily for the diagnosis of diseases associated with cyclooxygenase-2 (COX-2) overexpression. This product is a research-grade compound intended for laboratory research purposes, not for human therapeutic or diagnostic use. Further validation is required for clinical diagnostic applications. |
| Molecular Formula |
C16H31NO3
|
|---|---|
| Molecular Weight |
285.42
|
| Exact Mass |
285.23
|
| CAS # |
2097561-20-9
|
| PubChem CID |
137700331
|
| Appearance |
Typically exists as solid at room temperature
|
| Density |
1.0±0.1 g/cm3
|
| Boiling Point |
489.9±45.0 °C at 760 mmHg
|
| Flash Point |
250.1±28.7 °C
|
| Vapour Pressure |
0.0±2.8 mmHg at 25°C
|
| Index of Refraction |
1.487
|
| LogP |
3.77
|
| Hydrogen Bond Donor Count |
3
|
| Hydrogen Bond Acceptor Count |
3
|
| Rotatable Bond Count |
12
|
| Heavy Atom Count |
20
|
| Complexity |
266
|
| Defined Atom Stereocenter Count |
2
|
| SMILES |
C(N[C@@H](CO)[C@H](O)/C=C/CCCCCCCCC)(=O)C
|
| InChi Key |
CJDUQSUHEWFQMO-HMUVLFPJSA-N
|
| InChi Code |
InChI=1S/C16H31NO3/c1-3-4-5-6-7-8-9-10-11-12-16(20)15(13-18)17-14(2)19/h11-12,15-16,18,20H,3-10,13H2,1-2H3,(H,17,19)/b12-11+/t15-,16+/m0/s1
|
| Chemical Name |
N-[(E,2S,3R)-1,3-dihydroxytetradec-4-en-2-yl]acetamide
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
|---|
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.5036 mL | 17.5180 mL | 35.0361 mL | |
| 5 mM | 0.7007 mL | 3.5036 mL | 7.0072 mL | |
| 10 mM | 0.3504 mL | 1.7518 mL | 3.5036 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
